MX2016007179A - Metodos para el tratamiento de canceres hematologicos, y el uso de biomarcadores como predictores de la sensibilidad clinica frente a las terapias inmunomoduladoras. - Google Patents

Metodos para el tratamiento de canceres hematologicos, y el uso de biomarcadores como predictores de la sensibilidad clinica frente a las terapias inmunomoduladoras.

Info

Publication number
MX2016007179A
MX2016007179A MX2016007179A MX2016007179A MX2016007179A MX 2016007179 A MX2016007179 A MX 2016007179A MX 2016007179 A MX2016007179 A MX 2016007179A MX 2016007179 A MX2016007179 A MX 2016007179A MX 2016007179 A MX2016007179 A MX 2016007179A
Authority
MX
Mexico
Prior art keywords
biomarkers
methods
leanlidomide
clinical sensitivity
hematological cancers
Prior art date
Application number
MX2016007179A
Other languages
English (en)
Inventor
William Burnell Trotter Matthew
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2016007179A publication Critical patent/MX2016007179A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente se proporcionan, en ciertas modalidades, biomarcadores que se utilizan para predecir la sensibilidad clínica de cánceres hematológicos, como puede ser linfoma no Hodgkin, y las respuestas del paciente frente al tratamiento con un agente inmunornodulador como puede ser 2-(4-an-rino-1-oxo-1,3-d ihidro-isoindol-2-il)piperidin-2,6-diona, que también se conoce como lenalidomida o Revlimid(r). También se proporcionan en la presente, en ciertas modalidades, los métodos de tratamiento o manejo de linfomas no Hodgkin, que incluyen mas no se limitan a linfoma difuso de células B grandes (DLBCL), utilizando factores pronósticos.
MX2016007179A 2013-12-06 2014-12-05 Metodos para el tratamiento de canceres hematologicos, y el uso de biomarcadores como predictores de la sensibilidad clinica frente a las terapias inmunomoduladoras. MX2016007179A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361913046P 2013-12-06 2013-12-06
PCT/US2014/068767 WO2015085160A2 (en) 2013-12-06 2014-12-05 Methods for treating hematological cancers and the use of biomarkers as a predictor of clinical sensitivity to immunodulatory therapies

Publications (1)

Publication Number Publication Date
MX2016007179A true MX2016007179A (es) 2016-09-08

Family

ID=53274284

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007179A MX2016007179A (es) 2013-12-06 2014-12-05 Metodos para el tratamiento de canceres hematologicos, y el uso de biomarcadores como predictores de la sensibilidad clinica frente a las terapias inmunomoduladoras.

Country Status (12)

Country Link
US (1) US20160312292A1 (es)
EP (1) EP3077547A4 (es)
JP (1) JP2017503481A (es)
KR (1) KR20160090390A (es)
AU (1) AU2014360316A1 (es)
BR (1) BR112016012792A2 (es)
CA (1) CA2932266A1 (es)
EA (1) EA201691143A1 (es)
IL (1) IL245936A0 (es)
MX (1) MX2016007179A (es)
PH (1) PH12016501023A1 (es)
WO (1) WO2015085160A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160282354A1 (en) 2013-11-08 2016-09-29 The Broad Institute, Inc. Compositions and methods for selecting a treatment for b-cell neoplasias
CA3206268A1 (en) 2013-12-06 2015-06-11 Celgene Corporation Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
EP3996039A1 (en) * 2014-10-17 2022-05-11 Stichting Maastricht Radiation Oncology "Maastro-Clinic" Image analysis method supporting illness development prediction for a neoplasm in a human or animal body
JP6585737B2 (ja) 2015-06-02 2019-10-02 セルジーン コーポレイション セレブロン関連タンパク質の比を使用してがんの治療のための薬物の有効性を決定するための方法
EP3347717A4 (en) 2015-09-11 2019-06-05 The Brigham and Women's Hospital, Inc. METHODS OF CHARACTERIZING RESISTANCE TO CERTIFIED MODULATORS
EP3352756A1 (en) * 2015-09-25 2018-08-01 Celgene Corporation Methods for treating diffuse large b-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs
EP3399980A4 (en) 2016-01-08 2019-09-04 Celgene Corporation METHODS OF TREATING CANCER AND USE OF BIOMARKERS AS FACTORS PREDICTIVE OF CLINICAL SENSITIVITY TO TREATMENTS
US20200270703A1 (en) * 2017-09-29 2020-08-27 Kyushu University, National University Corporation Method and kit for predicting therapeutic effectiveness of chemotherapy for diffuse large b-cell lymphoma patients
CN115175903A (zh) * 2019-10-21 2022-10-11 新基公司 治疗血液癌症的方法和2-(2,6-二氧代哌啶-3-基)-4-((2-氟-4-((3-吗啉代氮杂环丁烷-1-基)甲基)苄基)氨基)异吲哚啉-1,3-二酮伴随生物标志物的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009085234A2 (en) * 2007-12-20 2009-07-09 Signal Pharmaceuticals, Inc. Use of micro-rna as a biomarker of immunomodulatory drug activity
KR20130038838A (ko) * 2010-03-12 2013-04-18 셀진 코포레이션 레날리도미드, 및 예측 인자로서 유전자 및 단백질 바이오마커를 사용한 비호지킨 림프종의 치료 방법
CN103688176A (zh) * 2011-04-29 2014-03-26 细胞基因公司 利用cereblon作为预报因子治疗癌和炎性疾病的方法

Also Published As

Publication number Publication date
EP3077547A4 (en) 2017-11-08
WO2015085160A2 (en) 2015-06-11
WO2015085160A3 (en) 2015-07-30
US20160312292A1 (en) 2016-10-27
EP3077547A2 (en) 2016-10-12
BR112016012792A2 (pt) 2017-08-08
PH12016501023A1 (en) 2016-07-04
AU2014360316A1 (en) 2016-06-16
JP2017503481A (ja) 2017-02-02
IL245936A0 (en) 2016-07-31
KR20160090390A (ko) 2016-07-29
EA201691143A1 (ru) 2016-11-30
CA2932266A1 (en) 2015-06-11

Similar Documents

Publication Publication Date Title
MX2016007179A (es) Metodos para el tratamiento de canceres hematologicos, y el uso de biomarcadores como predictores de la sensibilidad clinica frente a las terapias inmunomoduladoras.
GB2467467C (en) TAZ/WWTR1 for diagnosis and treatment of cancer
MX2019012714A (es) Anticuerpos y fragmentos anti-vista.
MX2015003985A (es) Combinacion de anticuerpos anti-kir y anticuerpos anti-dp-1 para tratar cancer.
PH12015502795B1 (en) An absorbent composite, an absorbent article employing the same, and methods, systems, and apparatus for making the absorbent composite and/or article
MX2020005165A (es) Biogenesis de miarn en exosomas para diagnostico y terapia.
SG10201907841UA (en) Adenovirus expressing immune cell stimulatory receptor agonist(s)
EP3054953A4 (en) Hdac inhibitors, alone or in combination with pi3k inhibitors, for treating non-hodgkin's lymphoma
TN2013000468A1 (en) Use of anti-cd19 maytansinoid immunoconjugate antibody for the treatment of b-cell malignancies symptoms
UA111175C2 (uk) ЗАСТОСУВАННЯ КОМПОЗИЦІЇ, ЯКА МІСТИТЬ БІСПЕЦИФІЧНЕ АНТИТІЛО CD19xCD3, ДЛЯ ЛІКУВАННЯ ДИФУЗНОЇ B-КРУПНОКЛІТИННОЇ ЛІМФОМИ
WO2009075797A3 (en) Biomarkers for predicting the sensitivity of cells to immunomodulatory compounds during treatment of non-hodgkin's lymphoma
EP2582847A4 (en) METHOD AND MATERIALS FOR EVALUATING THE LOSS OF HETEROZYGOTY
MX2015017807A (es) Sistema cerrado integrado de extraccion de linea intravenosa.
IL245766B (en) Different levels in blood cell samples of emt markers for the diagnosis of cancer, in particular colon cancer (crc) and pancreatic cancer (pc)
EP3495502A3 (en) Biomarkers for premature birth
MY193895A (en) Combination test for colorectal cancer
EA201401201A1 (ru) Способ
MX2015010023A (es) Anticuerpos anti-cd83 y su uso.
GB2465907A (en) VHZ for diagnosis and treatment of cancer
MX2018003697A (es) Metodos para el tratamiento de linfoma difuso de linfocitos b grandes y uso de biomarcadores como predictores de receptividad a farmacos.
MX363679B (es) Metodo para diagnosticar cancer.
WO2014179737A3 (en) Assays and methods of treatment relating to vitamin d insufficiency
EP3457138A3 (en) Novel biomarkers for acute myeloid leukemia
WO2014184684A3 (en) Methods and biomarkers for detection of hematological cancers
WO2014126796A3 (en) Methods of diagnosing, treating and monitoring diabetic retinopathy